Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476468 | 0.70 | CDC25B (0.35) | — | |
| SCHEMBL31073661 | 0.66 | — | — | |
| SCHEMBL8741635 | 0.63 | — | — | |
| SCHEMBL8141482 | 0.63 | KDM4E (0.39) | ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL1551085 | 0.63 | S100A4 (0.41) | ALDH1A1MAPTTDP1GAA | |
| SCHEMBL11519732 | 0.62 | NPC1 (0.44) | ALDH1A1MAPTTDP1HPGDGAA | |
| SCHEMBL19291 | 0.62 | NPC1 (0.44) | ALDH1A1MAPTTDP1HPGDGAA | |
| SCHEMBL29738149 | 0.62 | MGAM (0.37) | ALDH1A1MAPTHPGDKDM4EPOLB | |
| SCHEMBL29824404 | 0.62 | NCF1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL8331207 | 0.62 | KDM4E (0.38) | ALDH1A1MAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107814793-A | A kind of preparation method of small molecule Src tyrosine kinase inhibitors saracatinib and its intermediate | 胡张艳 | 2018-03-20 | — | — | CN | disclosed |
| EP-2252595-B1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8618290-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| WO-2013064919-A1 | QUINAZOLINE DERIVATIVES WITH HSP90 INHIBITORY ACTIVITY | DAC SRL (IT) | 2013-05-10 | — | — | WO | disclosed |
| EP-2313412-B1 | NOVEL DERIVATIVES OF PYRROLOINDOLE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI SA (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-1885701-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | Novartis Vaccines and Diagnostics, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1885701-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | Novartis Vaccines and Diagnostics, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2006113498-A3 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | CHIRON CORP (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006113498-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113498-A2 | 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | TYMP, TPMT, TYMS | ALDH1A1 1413/4885MAPT 106/4885TDP1 61/4885 |
| US-20120264770-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | ALDH1A1 1601/4885MAPT 1094/4885TDP1 959/4885 |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | ALDH1A1 1718/4885MAPT 457/4885TDP1 150/4885 |
| US-20120172321-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | ALDH1A1 1601/4885MAPT 1094/4885TDP1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.